2026 Trends in Drug Benefit Design Report
PSG announces the results of its extensive research on the latest trends in drug benefit design. Plan sponsors face complex decisions and challenges…
Read Post
Insights
Categories
Topics
Categories
Topics
2024 PBM Customer Satisfaction Report
PSG’s PBM Customer Satisfaction Report provides the most in-depth picture of the PBM landscape today. This research equips plan sponsors with data-driven insights to…
Read Post
Pharmaceutical Strategies Group Launches First-in-Class Technology Solution For Healthcare Payers
The Tool Will Help Anticipate Exposure for Newly-Approved Gene Therapies DALLAS, TX – September 10, 2024 – Pharmaceutical Strategies Group (“…
Read Post
Medicare Publishes Results of the Drug Price Negotiation Program
Plans must evaluate the adverse impact of the published Drug Price Negotiation Program On August 15, 2024, the Centers for Medicare and Medicaid Services…
Read Post
Wells Fargo PBM Lawsuit: Key Lessons For Employer Fiduciary Responsibility
Independent pharmacy benefit consulting is key to maintaining fiduciary responsibility. In July of 2024, four former Wells Fargo employees filed a…
Read Post
Pharmaceutical Strategies Group Strengthens Employer Pharmacy Benefit Consulting with Key Leadership Addition
DALLAS, TX – August 20, 2024 – Pharmaceutical Strategies Group (“PSG”), an EPIC company, announces the appointment…
Read Post
Celebrating 30 Years of Shared Success
Three Decades of Innovation, Independence, and Expertise at PSG “Our values don’t change. They are enduring,” said PSG President Michael Lonergan in an interview…
Read Post
RSV Vaccination 2024: What Payers Need to Know for Effective Coverage
Payers Can Optimize Health Outcomes and Cost Management for RSV Vaccination Coverage by Understanding Several Considerations With all the focus on flu and COVID-19…
Read Post
M3P Implementation: A Strategic Guide for Timely and Successful Rollout
Plans can achieve a seamless and timely M3P implementation through a strategic approach. In a recent blog, we outlined the…
Read Post
GLP-1 Resource Hub
Resources to Support Payers’ GLP-1 Strategies GLP-1s are a class of medications that can help manage type 2 diabetes and obesity. In recent years,…
Read Post
GLP-1 Trends Infographic
Learn more about trends in GLP-1 perceptions and coverage strategies Obesity is one of the largest public health concerns in the United States, and…
Read Post
Pharmaceutical Strategies Group Releases Artemetrx State of Specialty Spend and Trend Report
DALLAS, TX – June 11, 2024 – Pharmaceutical Strategies Group (“PSG”), an EPIC company, releases its proprietary Artemetrx® State of Specialty…
Read Post